1-3 of 3
Manish Gupta, PhD
Close
Sort by
Journal Articles

Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)

Tommy Li, PhD, Ida H Hiemstra, PhD, Christopher Chiu, PhD, Roberto S Oliveri, MD PhD, Dena DeMarco, Theodora W. Salcedo, PhD DABT, Frederikke Lihme Egerod, PhD, Manish Gupta, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-139457
Published: 2020
Journal Articles

Pan-BCL-2 Family Small Molecule Inhibitor GX015-070 (GeminX, Inc.) Exhibits Single Agent Cytotoxicity, Is Synergistic with Select Anti-Leukemia Cytotoxic Agents, and Induces Apoptosis in Cell Lines with t(4;11)(q21;q23) Translocations.

Jessicca M. Rege, PhD, Blaine W. Robinson, PhD, Manish Gupta, PhD, Jeffrey S. Barrett, PhD, Peter C. Adamson, MD, Kathryn C. Behling, MD, PhD, Andrew D. Bantly, Jonni S. Moore, PhD, Carolyn A. Felix, MD
Journal: Blood
Blood (2005) 106 (11): 3368.
https://doi.org/10.1182/blood.V106.11.3368.3368
Published: 2005
Journal Articles

Pre-Clinical In Vitro Evaluation of BCL-2 Antisense Compound Genasense TM (G3139; Genta, Inc.) as a Targeted Pro-Apoptotic Agent for Leukemias with t(4;11)(q21;q23) Translocations.

Blaine W. Robinson, PhD, Kathyrn C. Behling, MD, PhD, Jeffrey S. Barrett, PhD, Manish Gupta, PhD, Jessicca M. Rege, PhD, Jonni S. Moore, PhD, Andrew D. Bantly, Junhyong Kim, PhD, George Hii, Cheryl L. Willman, MD, Jeffrey Potter, Peter C. Adamson, MD, Carolyn A. Felix, MD
Journal: Blood
Blood (2005) 106 (11): 3360.
https://doi.org/10.1182/blood.V106.11.3360.3360
Published: 2005